Transforming growth factor beta 1 (TGF-b1) upregulation has been implicated in hypertrophic scars and keloids, but it is unclear if it is the cause or an effect of excessive scar formation. In this study, we overexpressed TGF-b1 in fibroblasts and characterized its role. Normal human dermal fibroblasts were genetically modified to overexpress TGF-b1 as the wild-type latent molecule or as a mutant constitutively active molecule. TGF-b1 secretion was measured, as were the effects of TGF-b1 upregulation on cell proliferation, expression of smooth muscle cell alpha actin (SMC a-actin) and ability to contract collagen lattices. Fibroblasts were implanted intradermally into athymic mice and tissue formation was analyzed over time by histology and immunostaining. Gene-modified fibroblasts secreted B20 times the TGF-b1 released by control cells, but only cells expressing mutant TGF-b1 secreted it in the active form. Fibroblasts expressing the active TGF-b1 gene had increased levels of SMC a-actin and enhanced ability to contract a collagen lattice. After intradermal injection into athymic mice, only fibroblasts expressing active TGF-b1 formed ''keloid-like'' nodules containing collagen, which persisted longer than implants of the other cell types. We conclude that upregulation of TGF-b1 by fibroblasts may be necessary, but is not sufficient for excessive scarring. Needed are other signals to activate TGF-b1 and prolong cell persistence.
INTRODUCTION
Fibrosis, the abnormal and excessive deposition of fibrous tissue, occurs in many diseases including liver cirrhosis, pulmonary fibrosis, scleroderma, and wound healing of the skin after trauma or surgery (O'kane and Ferguson, 1997) . Fibrosis in the skin can lead to the formation of abnormal scars, hypertrophic scars or keloids, which can cause significant problems in tissue growth, function, and movement. The problem is particularly acute following large deep second-and third-degree burns.
Keloids and hypertrophic scars are both benign proliferations of the dermis. A keloid is a dermal lesion that spreads beyond the margins of the original wound, continues to grow over time, does not regress spontaneously, and commonly recurs following treatment. By contrast, a hypertrophic scar is a raised scar that remains within the boundaries of the original lesion, often regresses spontaneously several months after the initial injury and rarely recurs after treatment. Clinically, treatment is challenging and despite a wide array of options (corticoids, radiation, lasers, surgery, and interferon), recurrence of keloids after treatment is frequent, varying from 45 to 100% (Niessen et al., 1999) .
There is little understanding of the molecular mechanisms leading to the formation of keloids or hypertrophic scars, nor is there an adequate animal model for their study, as they occur only in humans. A leading theory proposes that upregulation of transforming growth factor beta 1 (TGF-b1) expression drives excessive cell proliferation and matrix synthesis (Border and Noble, 1994) . TGF-b1 and its family members b2 and b3 are one of the only few cytokines known to stimulate collagen synthesis, and several studies have shown that it is upregulated in hypertrophic scars and keloids (Ghahary et al., 1993; Younai et al., 1994; Tredget et al., 1998; Lee et al., 1999; Wang et al., 2000; Hanasono et al., 2003) . It is also well known that TGF-b1 is an autocrine factor produced by fibroblasts that is capable of upregulating its own synthesis (Van Obberghen-Schilling et al., 1988; Tomasek et al., 2002) .
However, synthesis and activation of TGF-b1 and its family members b2 and b3 is a complex process. TGF-b1 is synthesized in a latent form as part of a large precursor molecule. TGF-b1 is proteolytically cleaved from the precursor as it is secreted, but remains noncovalently bound to the latency-associated peptide. Much of the TGF-b1-latencyassociated peptide complex is stored in the extracellular matrix because of the fact that latency-associated peptide is covalently bound to another protein, the latent TGF-b1-binding protein. Most importantly, TGF-b1 in this complex is inactive. Once released from this complex, TGF-b1 is active and can bind/signal its cellular receptor. TGF-b1 is liberated by extremes of pH and heat in vitro as well as by proteases such as furin and plasmin (Gleizes et al., 1997; Khalil, 1999) . Other proteins, such as thrombospondin, have been implicated in the release of TGF-b1 in vivo, although other mechanisms may be operable (Murphy-Ullrich and Poczatek, 2000) .
Although upregulation of TGF-b1 expression has been implicated in the formation of hypertrophic scars and keloids, it is unclear if it is the cause or merely an effect of the formation of these scars. Moreover, activation of TGF-b1 is probably a critical regulatory step in this process. In this study, we used genetic modification to directly test the hypothesis that TGF-b1 upregulation contributes to fibrosis in the skin. We genetically modified normal human dermal fibroblasts to overexpress TGF-b1 in one of two forms; the wild-type latent molecule or a mutant form that is constitutively active. The modified cells secreted high levels of TGFb1, but only cells transfected with the mutant gene secreted it in the active form. These cells also had increased levels of smooth muscle cell (SMC) a-actin and an enhanced ability to contract a collagen lattice. When implanted intradermally into athymic mice, only cells expressing the active mutant TGF-b1 formed nodules and these structures persisted longer than implants of control cells or cells overexpressing latent TGF-b1. The role of TGF-b1 in hypertrophic scars and keloids are discussed in light of these results.
RESULTS
Fibroblasts transfected with the mutant gene produce high levels of active Diploid human fibroblasts were genetically modified with a recombinant retrovirus encoding either wild-type (latent) TGF-b1, which is secreted as a latent molecule and requires activation, or a mutant form of TGF-b1 (cysteines 223 and 225 were converted to serines), which is secreted as an active molecule and does not require activation ( Figure S1 ). To determine how much TGF-b1 was secreted, control and gene-modified fibroblasts were grown to confluence and aliquots of the medium harvested at different time points, and levels of TGF-b1 measured by ELISA (Figure 1 ). To distinguish between TGF-b1 secreted in the latent form versus the active form, samples were either activated by acidification or not activated before ELISA. In samples that were activated, cells expressing the wild-type latent form of TGF-b1 accumulated 18 times more TGF-b1 than control unmodified cells after 48 hours, and cells expressing the mutant active form of TGFb1 accumulated 21 times the amount (Figure 1a) . The rates of total TGF-b1 production (latent plus active) were 2.6 ng/ 10 6 cells/48 h for control cells (1.1 ng/ml at 24 hours), 48.5 ng/10 6 cells/48 h for latent cells (17.9 ng/ml at 24 hours), and 56.7 ng/10 6 cells/48 h for mutant active cells (8.3 ng/ml at 24 hours). These ELISA data of activated samples measure the level of TGF-b1 in the latent as well as the active form. To determine how much TGF-b1 was secreted in the active form, the same samples were assayed without activation before ELISA (Figure 1b) . Cells expressing latent TGF-b1 accumulated the same amount of active TGF-b1 as control cells (0.22 ng/10 6 cells/48 h) (0.084 ng/ml at 24 hours), but the rate of active TGF-b1 production by cells expressing the mutant gene was 300 times higher (67.2 ng/10 6 cells/48 h) (4.4 ng/ml at 24 hours).
Proliferation is decreased in fibroblasts expressing active TGF-b1
To determine whether TGF-b1 expression altered fibroblast proliferation, control and modified cells were plated into sixwell plates, trypsinized and counted every day (Figure 2 ). For the first 48 hours, the proliferation of all cells was comparable. After 2 days, control and cells expressing latent TGF-b1 proliferated at comparable rates and reached confluence in 5 days. In contrast, cells expressing active TGF-b1 proliferated slower, and required an additional 48 hours to reach confluence ( Figure 2a ). The doubling time for control cells and cells expressing latent TGF-b1 was B20-24 hours versus B48 hours for cells expressing active TGF-b1. A similar result was obtained when performing the growth curve with WST-1 (Figure 2b ). After reaching confluence, cells were followed for up to 21 days to evaluate cell morphology (Figure 2c ). In the first few days, the cell morphology for all groups was comparable. By the end of 21 days, the slower growing cells expressing active TGF-b1 had about half as many cells (60 Â 10 4 cells/well) as control cells or cells expressing latent TGF-b1 (111 Â 10 4 ). One week after reaching confluence, cells expressing active TGF-b1 started to form aggregates and clusters that grew larger with time, whereas control cells and cells expressing latent TGF-b1 did not.
Levels of SMC a-actin are increased in fibroblasts expressing active To determine whether levels of SMC a-actin were altered, control and modified fibroblasts were grown to confluence and incubated in medium containing 1% serum for 48 hours. Cells were lysed with a buffer containing 1% SDS, and equal amounts of total protein were fractionated by SDS-PAGE, transferred to nitrocellulose membranes and probed by Western blotting. Compared to controls and cells expressing latent TGF-b1, cells expressing active TGF-b1 had increased levels of SMC a-actin (Figure 3a ). The same membrane was stripped and probed for b-actin, showing that differences in SMC a-actin levels were not due to differences in loading, as the levels of b-actin were comparable. To estimate the increase in SMC a-actin levels, varying amounts of total protein (5, 10, 15, and 20 mg) were loaded and probed by Western blotting. These data show that SMC a-actin levels were 2-3-fold higher in cells expressing active TGF-b1 versus control cells and cells expressing latent TGF-b1 (Figure 3b ).
Contraction of collagen lattices is enhanced by gene-modified fibroblasts
To evaluate the ability of fibroblasts to contract collagen lattices, control and modified cells were cast into floating collagen lattices and monitored contraction over time ( Figure 4 ). Collagen lattices were rapidly contracted by transfected cells from a starting diameter of 3.3 cm to less than 2 cm in the first 24 hours. Lattices with cells expressing latent TGF-b1 and active TGF-b1 contracted from 3.3 to 1.8 cm and 3.3 to 1.7 cm, respectively; whereas lattices with control cells contracted from 3.3 to 2.7 cm in the first 24 hours. After 144 hours, contraction was greatest for cells expressing active TGF-b1 (32% of its initial diameter) compared to cells expressing latent TGF-b1 (58%) and control cells (63%).
Cells expressing active TGF-b1 form nodules and persist longer after implantation
To evaluate their growth and tissue organization in vivo, control and gene-modified fibroblasts were implanted by intradermal injection into athymic mice. Injection sites were excised and pictures taken at each time point ( Figure S2 ). At 3 days after injection, cells expressing latent or active TGF-b1 formed macroscopic nodules that were visible on the inner side of the skin. Nodule formation by control cells was not obvious. At 7, 10, and 14 days after injection, nodules were only obvious for those cells expressing active TGF-b1 and they had an enhanced macroscopic vascularization, mainly at 7 days. Compared to their size at day 7, nodules formed by cells expressing active TGF-b1 were somewhat smaller and appeared to be contracted at days 10 and 14. At day 28 and beyond, macroscopic nodules were not apparent for any of the cell groups. These results were found in all animals tested (eight animals/time point) with minimal variations in nodule size and time of formation and disappearance. To examine their organization, the sites of injection were evaluated by histology (hematoxilin & eosin) ( Figure 5 ). At days 3 and 7, the injection sites for modified cells as well as control cells could be identified even though the control cells did not form a visible nodule. At these early time points, the injection sites of all groups had areas of high cell density that were approximately the same size, except for cells expressing active TGF-b1 that were bigger, and with little tissue organization. Control cells and cells expressing latent TGFb1 tended to be more spread out from the injection site, whereas cells expressing active TGF-b1 were collected in a more sphere-like formation. Compared to control cells, blood vessels seemed more abundant for cells expressing active TGF-b1, followed by cells expressing latent TGF-b1. From day 10 onward, it was difficult to conclusively identify the control cells and those expressing latent TGF-b1, whereas cells expressing active TGF-b1 formed distinct nodules, most obvious at day 14. At this point, cell density of the nodules was lower than sites at early times after injection and cell density was not homogenous. Nodules had the highest density of cells at the periphery and a decrease in cell density toward the center. The entire nodule also appeared to be encapsulated by mouse connective tissue. Blood vessels were located predominately around the periphery of the nodule. Nodules formed by cells expressing active TGF-b1 persisted for as long as day 28 but decreased significantly in size.
To definitively identify which cells were human fibroblasts, cryosections were immunostained with a monoclonal antibody that recognizes human vimentin and does not crossreact with murine vimentin (Figure 6 ). Immunostaining confirmed, that at all time points for all groups where a nodule was macroscopically visible, it contained human fibroblasts. Immunostaining also revealed human fibroblasts, even if no nodule was visible. Control cells and cells expressing latent TGF-b1 were detected 28 days after injection. These cells were fewer in number and were more integrated into the mouse tissue than cells expressing active TGF-b1. Active TGF-b1-expressing cells were generally confined to a nodule. Immunostaining also revealed that the cells in the center and the periphery of the nodules were human cells and clearly showed the boundary between human cells and the mouse cells encapsulating the nodule. When immunostained for collagen type 1, it was clear the entire nodule contained abundant collagen, and the injected human cells were producing collagen.
DISCUSSION
Keloids and hypertrophic scars are manifestations of an abnormal process of tissue repair after trauma to the skin. Options for treatment are limited by our lack of understanding of the molecular and cellular mechanisms governing the formation of these scars. Moreover, as these lesions are unique to humans, animal models for the development of new therapeutic interventions are severely limited. Current models, based on the implantation of human scar tissue into athymic animals are cumbersome, limited by the availability and variability of human tissue and are not widely used, nor have they been used to pinpoint the molecular and cellular events underlying these scars (Estrem et www.jidonline.org 1171 AB Campaner et al.
TGF-b1 induces collagen synthesis and has been shown to be upregulated in scars and so a leading hypothesis is that chronic overexpression of TGF-b1 or one of its fellow family members b2 and b3 drives the formation of keloids and hypertrophic scars. Yet, each TGF-b is secreted as a latent molecule that requires activation and no study has established a cause and effect relationship between TGF-b overexpression and the formation of keloids or hypertrophic scars. To investigate the role of TGF-b1 and its activation in fibrosis of the skin, we genetically modified diploid human skin fibroblasts to overexpress either wild-type TGF-b1, which is secreted in a latent form, or mutant TGF-b1, which is secreted in a constitutively active form. The mutations at positions 223 and 225 (cysteines to serines) are located in the latency-associated peptide portion of the gene and do not alter the mature TGF-b1 polypeptide sequence; however, they do disrupt latency-associated peptide folding and prevent the formation of the latent complex with TGF-b1 (Brunner et al., 1989) . Modified fibroblasts expressing the wild-type gene secreted 18-fold more TGF-b1 than control cells, but it was in the latent form and levels of active TGF-b1 released by these cells were comparable to controls. In contrast, modified fibroblasts expressing the mutant gene secreted 21-fold more TGF-b1 than control cells and it was in the active form. These data show that human fibroblasts are able to synthesize high levels of wild-type TGF-b1, but they are unable to activate it. Moreover, these data show that levels of secreted TGF-b1 (latent or active) are not limited by the levels of latent TGF-b-binding protein gene expression (Myazono et al., 1991; Saharinen et al., 1996) . Others have used a gene transfer approach to overexpress TGF-b1 in the skin via transgenic animals or direct gene transfer (Sellheyer et al., 1993; Benn et al., 1996) .
Fibroblasts expressing active TGF-b1 proliferated slower than either control cells or fibroblasts overexpressing latent TGF-b1. Prior studies have shown that TGF-b1's action on fibroblast proliferation is complex. Proliferation of mink lung fibroblasts is stimulated by low concentrations of TGF-b1 (5-10 ng), and inhibited by higher concentrations (Ghahary et al., 2002) , whereas cell proliferation of post confluent cultures of human dermal fibroblasts is stimulated by TGF-b1 (Clark et al., 1997) . In most proliferation studies, cells are exposed to a bolus of active TGF-b1, whereas in our study, cells are continually exposed to TGF-b1 (latent or active) during the entire time they are cultured. In fact, when cells were grown beyond confluence, only those cells expressing active TGF-b1 formed distinct cell clusters or aggregates. Based on observations from a prior study where fibroblasts treated with TGF-b formed stratified cell layers interposed by abundant extracellular matrix, our cell clusters could be sites of excessive extracellular matrix deposition that stimulated the local contraction of cells into aggregates (Clark et al., 1997) . This may be a dose-dependent phenomenon and so it would be interesting to select for gene-modified cells expressing different levels of TGF-b and determine its influence on cell proliferation.
TGF-b1 is thought to induce the differentiation of fibroblasts into myofibroblasts that reorganize extracellular matrix and exert tensile forces on the provisional matrix of healing wounds (Rudolph et al., 1992; Tomasek et al., 2002) . Compared to control cells and cells expressing latent TGF-b1, fibroblasts expressing active TGF-b1 had a 2-3-fold increase in the expression of SMC a-actin, a marker of myofibroblasts that is upregulated by TGF-b1 (Desmoulière et al., 1993; Serini and Gabbiani, 1996; Tomasek et al., 2002) . Moreover, contraction of collagen lattices was greatest for cells expressing active TGF-b1 versus control cells. Interestingly, contraction was also enhanced, but not as much, by cells expressing latent TGF-b1, even though they did not express higher levels of SMC a-actin. This is a consistent observation and may be a limitation of the collagen gel contraction assay possibly due to local effects (eg, pH) or the presence of other factors in the serum or collagen preparation that may activate TGF-b1.
When injected intradermally into athymic mice, the tissue organization of fibroblasts expressing active TGF-b1 was distinctly different than control cells or cells expressing latent TGF-b1. These cells formed macroscopically evident nodules that were well vascularized, appeared to contract with time and persisted longer than controls or cells expressing latent TGF-b1. At early times, cell density of control and both types of modified cells was high and the cells had little if any organization. Over time, cell density decreased for all groups and cells expressing active TGF-b1 formed distinct nodules encapsulated by mouse connective tissue. Within a nodule, the density of human fibroblasts was greatest around the periphery with few cells in the center that contained abundant collagen. These features show similarities to the histology of keloids and hypertrophic scars, although these lesions are often confused and there is significant overlap in their histology. Keloids are characterized by the presence of whorls of thick, hyalinized collagen bundles or keloidal collagen with mucinous ground substance and relatively few fibroblasts; hypertrophic scars are characterized by nodular structures with fine randomly organized collagen fibers (Ehrlich et al., 1994; Lee et al., 2004) . However, unlike keloids that grow and hypertrophic scars that persist long term, nodules formed by fibroblasts expressing active TGF-b1 decreased in size over time.
These data demonstrate that upregulation of TGF-b1 by fibroblasts may be necessary but it is not sufficient for the formation of keloids or hypertrophic scars. This conclusion is supported by the observation that only those fibroblasts expressing active TGF-b1, but not fibroblasts overexpressing the wild-type latent TGF-b1 gene, formed keloid-like nodules. Thus, simple upregulation of the TGF-b1 gene, as seen in keloids or hypertrophic scars (Ghahary et al., 1993; Younai et al., 1994; Tredget et al., 1998; Lee et al., 1999; Wang et al., 2000; Hanasono et al., 2003) , is not enough. Present in the scar environment must also be a signal that activates latent TGF-b1. Although latent TGF-b1 can be activated by heat, extremes of pH, chaotropic agents and detergents, the physiological relevance of these is unknown. More relevant to scars is the fact that latent TGF-b1 is activated by glycosidases, proteases such as plasmin and cathepsin D and interaction with the adhesive protein thrombospondin-1 (Gleizes et al., 1997; Khalil, 1999) .
Even if TGF-b1 is activated, as was the case for our fibroblasts expressing mutant active TGF-b1, the keloid-like structures that these cells formed, decreased in size with time. Parallel to this decrease in nodule size was a significant loss of cells and a decrease in cell density at the injection site. These data suggest that another signal must also be present that either serves to maintain scar size, as is the case for hypertrophic scars, or to expand scar size, as is the case for keloids. We hypothesize that formation of keloids and hypertrophic scars is a multistep process. Signals that serve to maintain scar size might include apoptosis inhibition (Desmoulière et al., 1995; Sayah et al., 1999; Teofoli et al., 1999; Luo et al., 2001; Nakazono-Kusaba et al., 2004) . Signals that might stimulate the growth and expansion of a scar might include platelet-derived growth factor (PDGF), a factor well known for its ability to stimulate fibroblast proliferation (Deul, 1987; Messadi et al., 1998) , or other factors like basic fibroblast growth factor and connective tissue growth factor (Frazier et al., 1996; Takehara, 2000) . Moreover, several reports using a surgical model of scar implantation into athymic rats have suggested that TGF-b2 and not TGF-b1 has a causative role in the formation of proliferative scars (Polo et al., 1999; Smith et al., 1999; Wang et al., 1999 and others have reported that a dysregulated response to glucocorticoids may contribute to the pathology (Russell et al., 1995) .
Recombinant retroviruses can be used for the stepwise genetic modification of human fibroblasts to express multiple factors and the tissue organization of these cells can be evaluated by intradermal injection as was done in this paper. In this new approach to an animal model for studying the steps to excessive scarring, we may be able to define tissue structures that are intermediates to either a keloid or a hypertrophic scar caused by the dysregulation of specific growth factors and define the role of specific genes and signaling pathways. The increased understanding of the molecular and cellular events leading to the formation of keloids and hypertrophic scars gained by this approach as well as other approaches such as the biochemical characterization of fibroblasts from keloids/hypertrophic scars, the implantation of human proliferative scars, the sustained in vivo delivery of factors that promote fibrosis and the use of transgenic animals may lead to new therapeutic options.
MATERIALS AND METHODS

Culture of human cells
Human dermal fibroblasts were derived from neonatal foreskins, obtained at the Women & Infants Hospital of Rhode Island, Providence, RI (approved by the Institutional Review Board and in adherence to the Declaration of Helsinki Principles). Foreskins were trimmed with scissors to remove excess fatty tissue, rinsed repeatedly with sterile phosphate buffer solution (PBS), and diced into small fragments. The fragments were allowed to adhere to the bottom of a tissue culture plate in a humidified 10% CO 2 atmosphere, at 371C for 1 hour, and were covered with DMEM (Gibco, Grand Island, NY) supplemented with 20% fetal bovine serum (Hyclone, Logan, UT) containing 100 U of penicillin and 100 mg of streptomycin (Gibco) per ml. Over a period of 14 days, fibroblasts migrated from the tissue fragments and formed a confluent layer on the culture plate. Fibroblasts were harvested with a 0.05% trypsin/EDTA (Gibco) solution and subcultured in DMEM containing 10% fetal bovine serum and penicillin/streptomycin.
Retroviral constructs and genetic modification
The retroviral vector, MFG-TGF-b1 was assembled in a two-step process to remove all 5 0 and 3 0 noncoding sequences of the wildtype human TGF-b1 cDNA. A fragment from the 5 0 end of TGF-b1 (BglI to BamHI) was isolated, combined with a double-stranded oligonucleotide (5 0 -CATGCCGCCCTCC-3 0 and 5 0 -GGGCGG-3 0 ) and ligated as a three-part ligation into purified MFG vector that had been previously cut with NcoI and BamHI. This intermediate clone, containing the TGF-b1 5 0 end, was cut with BamHI, treated with calf intestinal phosphatase and gel purified. Into this BamHI site was cloned a PCR product of the remaining 3 0 end of the TGF-b1 cDNA.
This PCR product, prepared using a forward primer (5 0 -GAAGTGG ATCCACGAGCCCAAGGGCT-3 0 ) and a reverse primer (5 0 -CTG CTGGATCCAGATCTTCAGCTGCACTTGCAGGAGCG-3 0 ) was digested with BamHI and gel purified. A similar strategy was used to construct an MFG retrovirus encoding a mutant form of TGF-b1 that is secreted as an active molecule and that does not require activation (Brunner et al., 1989) . In this case, cysteines at positions 223 and 225 were converted to serines. The sequences of the final vectors encoding either wild-type (latent) TGF-b1 or mutant (active) TGF-b1 were verified by DNA sequencing. Vectors were transfected into a packaging cell line to generate a stable cell line producing recombinant retrovirus. The passage 4 fibroblasts were genetically modified as previously described (Morgan et al., 1995 , Le Doux et al., 2001 ). Briefly, virusproducing cells were grown to confluence in a 10 cm dish, the medium changed (10 ml/plate) and after 24 hours, the medium was removed, filtered using a 0.45 mm filter, and stored at À801C. For transduction, 1.15 Â 10 5 fibroblasts were plated in a 35 mm dish and incubated overnight. Stocks of recombinant retrovirus were thawed and brought to 80 mg/ml of chondroitin sulfate C from shark cartilage (Sigma, St Louis, MO) using a 100 Â stock. After incubation for 10 minutes at 371C, the virus stock was then brought to 80 mg/ml of polybrene (hexadimethrine bromide, 1,5-dimethyl-1,5-diazaundecamenthylene polymethobromide) (Sigma) using a 100 Â stock and incubated for an additional 10 minutes at 371C. The solution was centrifuged at 10,000 r.p.m. in a 1.5 ml microcentrifuge tube for 5 minutes at room temperature. The visible pellet was resuspended in cell culture medium to one-tenth of its original volume. The medium of the human fibroblasts was aspirated and the virus solution was added and incubated for 24 hours at 371C. The medium was removed and the cells washed once with fresh culture medium, and then replaced with new medium. After another 24 hours, the cells were trypsinized and transferred to 10 cm dishes and grown to confluence.
Measurement of growth factors levels by ELISA
Control and genetically modified fibroblasts were grown to confluence in 10 cm dishes and incubated 48 hours in 1% serum medium. The medium was changed, aliquots harvested at different time points, and levels of TGF-b1 measured by ELISA (R&D Systems, www.jidonline.org 1173 AB Campaner et al.
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Minneapolis, MN). The antibodies used in the ELISA kit are only able to detect TGF-b1 in its active form, thus samples are routinely activated by acidification (HCl) before ELISA. To measure levels of latent and active TGF-b1, samples were activated according to the manufacturer's instructions. To measure levels of TGF-b1 that were secreted in the active form, the activation step was omitted. After harvesting the last time point, cells were treated with trypsin, counted and the values of TGF-b1 were normalized by the volume of medium in the dish at each time point divided by the final cell number.
Measurement of cell proliferation
Control and modified cells (3 Â 10 3 cell/cm 2 ) were plated in six-well plates (triplicate) in medium containing 10% serum. Cells were trypsinized and counted in a hematocytometer daily, until reaching confluence. Cell viability and proliferation were also assessed with the WST-1 reagent (Roche Diagnostics Corp, Indianapolis, IN) according to the manufacturer's recommendations. Cells of each cell type were plated in a 96-well dish (1 Â 10 3 per well) in triplicate with 100 ml of medium and incubated for 24 hours. Daily up to 7 days, 10 ml of the Wst-1 reagent was added to each well, incubated for 2 hours at 371C and read with an ELISA plate reader at 450 nm. Cells were followed in culture for up to 3 weeks, and phase contrast microscopy (Olympus IX70 microscope with a Axio Cam MRc camera and MRGrab 1.0 Software) (Carl Zeiss Vision GmbH, Germany) was used to document changes in cell morphology over time.
Western blot analysis
Control and modified fibroblasts were grown to subconfluence in 60 mm dishes and incubated 48 hours in medium containing 1% serum. The medium was changed and after 48 hours, cells were lysed with a buffer containing 1% SDS (Sigma). Protein concentration was determined by bicinchoninic acid (BCA) assay (Sigma). Cell extracts were mixed with an equal volume of SDS sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 2% bromophenol blue, and 5% b-mercaptoethanol) and boiled at 1001C for 5 minutes. Equal amounts of total protein (5-10 mg) were loaded onto 7% SDSminigels and separated by PAGE. Separated proteins were transferred by electrophoresis to a Hybond ECL nitrocellulose membrane (Amersham Biosciences Corp, Piscataway, NJ) overnight at 41C, in a buffer containing 25 mM Tris, 192 mM glycine, 20% methanol (vol/ vol) . Membranes were treated with blocking buffer (5% nonfat dry milk, 0.05% Tween 20 in PBS) at room temperature for 2 hours. Following a brief rinse, membranes were probed with a mouse monoclonal antibody to SMC a-actin (1:4,000 dilution in blocking buffer, clone 1A4, Sigma) for 2 hours at room temperature. This was followed by 3 washes of 5 minutes each in PBST (0.05% Tween 20 in PBS). Subsequently, membranes were incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (1:10,000 in blocking buffer; Chemicon, Temecula, CA) at room temperature for 1 hour. Following three washes in PBST, the immunoblots were then incubated with Supersignal West Pico chemiluminescence substrate (Pierce, Rockford, IL) for 5 minutes and exposed to X-OMAT Kodak film. The membranes probed for SMA a-actin were stripped with 2% SDS, 100 mM mercaptoethanol in 62.5 mM Tris-HCl, pH 6.8 for 30 minutes at 701C, and reprobed with a mouse monoclonal antibody to b-actin (1:5,000 in blocking buffer, clone AC-15, Sigma), followed by the same procedure. For quantitation, the films corresponding to each Western blot were photographed using the Kodak Electrophoresis Documentation and Analysis System 290 (EDAS 290), and analyzed with the Image J Software (National Institute of Health) obtaining the sum of the pixel values of band areas. Densitometric analysis results were presented as fold increase.
Measurement of collagen lattice contraction by fibroblasts
Before preparing the gels, 5 ml of BSA (Sigma) solution (0.1% BSA in PBS, filter sterilized) was pipetted into each well of a six-well plate, incubated at 371C for 1 hour. 1.4 ml of bovine dermal collagen Vitrogen (Cohesion, Palo Alto, CA) was mixed with 0.4 ml of 5 Â DMEM in a 15 ml centrifuge tube cooled on ice. The pH was adjusted to a range of 7.2-7.5, using a sterile solution of 1 N NaOH. The control and modified cells were trypsinized from a confluent tissue culture plate and 0.2 ml of the cell suspension (containing 5 Â 10 5 cells) was added to the collagen solution, gently mixed and poured into a well of the six-well plate. Collagen lattices were allowed to gel for 60 minutes in a 5% CO 2 atmosphere at 371C. After 60 minutes, the collagen lattices were detached from the surface of the well by rimming the lattice with a sterile spatula and gently swirling the six-well plate. Four milliliters of serum-free medium was added to each well. Plates were incubated in a 10% CO 2 atmosphere at 371C, and the medium changed every 2 days. To measure contraction, the tissue culture dishes were periodically placed on top of a transparent metric ruler on an opaque background, and the diameters of the lattices were recorded as the average values of the major and minor axes (Pins et al., 2000) . Experiments were repeated 6 times and the values presented with the standard deviation.
Cell implantation into athymic mice
NCr athymic outbread mice, 5-6-week-old males, were purchased from Taconic (Germantown, NY), and acclimated for 1 week before undergoing any procedure. All procedures were approved by the Brown University Animal Care Committee and carried out in accordance with the National Institute of Health Guide For The Care And Use Of Laboratory Animals. Confluent fibroblasts (modified and unmodified) contained in a triple flask (500 cm 2 ) were trypsinized, counted and pelleted by centrifugation. The pellet was resuspended in DMEM and placed in a 28-gauge 1 ml disposable insulin syringe (Becton-Dickinson, Frankin Lakes, NJ). Intradermal injection of cells into the dorsal skin (0.1 ml of DMEM with 1 Â 10 6 cells) was administered immediately following cell preparation. Mice were anesthetized using inhalatory isofluorane (Baxter, Deerfield, IL). Each mouse was injected with duplicates of control (unmodified cells), cells expressing latent TGFb1, cells expressing active TGF-b1, and vehicle alone (DMEM). The skin was marked with a permanent marker to indicate the injection sites, which were separated by 1 cm of nontreated skin. A Tegaderm TM (3M, St Paul, MN) dressing was applied after injections to prevent the animal from disturbing the sites. Animals were killed by CO 2 asphyxiation at days 3, 7, 10, 14, 21, and 28. A total of four batches of animals were used, with two animals for each time point. All animals survived throughout the experiments.
One injection site was fixed in 10% formalin and embedded in paraffin for routine histology. The other injection site was immediately embedded in Tissue-tek OCT compound (Sakura Finetek Inc., Torrence, CA) and snap frozen for immunostaining. There was no tissue response when vehicle without cells was injected.
Histology and immunostaining
Paraffin-embedded samples were sectioned (5 mm) and stained with hematoxylin and eosin. For immunostaining, frozen sections (8 mm) were fixed in cold acetone (À201C) for 2 minutes, rinsed in PBS and incubated in a solution of four parts methanol to one part of 6% H 2 O 2 (in PBS) for 20 minutes to block endogenous peroxidase activity. Nonspecific binding sites were blocked for 1 hour in 10% goat serum (Sigma) and 5% BSA in PBS. Sections were incubated with a mouse monoclonal anti-vimentin, clone V9 (DakoCytomation, Carpinteria, CA), diluted 1:50 in the blocking solution for 1 hour at room temperature in a humidified container. Sections were washed 3 times in PBS, incubated 30 minutes in blocking buffer and 30 minutes with a biotinylated HRP-conjugated secondary antibody goat anti-mouse (Chemicon) diluted 1:2,500 in blocking buffer. Sections were developed with 3, 3 0 , 5, 5 0 -tetramethylbenzidine for 10 minutes (Vector, Burlingame, CA). For collagen staining, serial sections were incubated with a mouse monoclonal anticollagen type I (Chemicon) diluted 1:20 in blocking buffer overnight at 41C, incubated with the secondary antibody as above (1:,1000 in blocking buffer) for 4 hours, and developed with 3, 3 0 -diaminobenzidine (Vector). Negative controls were prepared using the same tissue and were stained with primary antibody alone, secondary antibody alone and substrate alone. Pictures were taken using an Olympus IX70 microscope with an Axio Cam MRc camera and MRGrab 1.0 Software (Carl Zeiss Vision GmbH, Germany).
Statistics
Statistical comparisons between sample groups were made using an analysis of variance with Pp0.05 indicating a significant difference between the groups.
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SUPPLEMENTARY MATERIAL Figure S1 . Complex pathway for synthesis, secretion, and activation of TGF-b1. Figure S2 . Implanted fibroblasts expressing active TGF-b1 form nodules that persist.
